FoundationOne Liquid CDx is now FDA-approved to identify mNSCLC patients with MET exon 14 skipping alterations for tepotinib ...
It reported the medication was effective at increasing the rate of growth by 2.5cm a year for up to 18 months during treatment, increasing overall height and improving the upper-to-lower-body segment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback